October 15, 2012
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of home health care services provider Amedisys (Nasdaq: AMED ) are crawling back into bed today, falling as much as 11%, after announcing a new health services contract with Humana (NYSE: HUM ) .
So what: A new contract and the stock is down... "What gives?" right? Well, the reason Amedisys is tanking has to do with the fact that the new home health services contract will be paid out on a per-visit basis as opposed to a previously agreed upon episodic basis. Because of this, Amedisys expects to generate only half of its normal $65 million-$70 million in revenue that it usually generates annually from its relationship with Humana. Management noted the reduction in revenue will begin in the fourth quarter.
Now what: The fact that Amedisys is having to rework some of its health services contracts really isn't a surprise. What we need to remember is that today's revenue reduction from the Humana deal lops about 2% off of future revenue, yet the stock is shedding in the low double digits. That seems to be a bit of an overreaction. I also feel it's worth pointing out that while the Affordable Care Act will constrain health care service providers' ability to boost pricing, it should bring a new class of insurable patients into health care insurers' networks. Ultimately, I feel the ACA could cause Amedisys' revenue to head higher consistently, and I consider the company a tempting value play here.
Craving more input? Start by adding Amedisys to your free and personalized Watchlist so you can keep up on the latest news with the company.
More Expert Advice from The Motley Fool
The Motley Fool's chief investment officer has selected his No. 1 stock for the next year. Find out which stock in our brand-new free report: "The Motley Fool's Top Stock for 2013
." I invite you to take a copy, free for a limited time. Just click here
to access the report and find out the name of this under-the-radar company.